Abstract 2408
Background
The anti-tumor activity of Ctx after ICIs has been poorly investigated in patients with refractory advanced solid tumors. A recent communication suggested that ICIs may sensitize Non-Hodgkin Lymphoma to subsequent Ctx (Nicole A, Carreau et al, ASH 2019) but a control arm with exposure to alternative non-ICI therapy was missing.
Methods
From a prospective cohort of patients (pts) treated with ICIs (n = 310) or targeted agents (TAs) (n = 281) in Phase I trials at Vall d´Hebron Institute Oncology in the last 7 years, 31 (10.0%) and 52 (18.5%) received Ctx within 4 months after exposure to ICIs or TA, respectively. The aim of this study was to compare response rate (RR) and progression free survival (PFS) of subsequent Ctx after ICIs versus TAs. A propensity score (PS) matched analysis was performed to adjust for clinical-pathological heterogeneity between cohorts.
Results
In the overall study population, RR with Ctx after ICIs included partial response (PR) in 5 pts (16.1%), stable disease (SD) in 6 pts (16.4%) and progressive disease (PD) in 20 pts (64.5%). When Ctx was given after TAs, we found PR in 4 pts (7.7%), SD in 18 pts (34.6%) and PD in 30 (57.7%). Differences in RR with Ctx after ICIs or TAs were not significant (p = 0.43). Factors linked with higher RR were number of previous treatment lines (OR 0.51, p = 0.05) and breast cancer vs. other malignancies (OR 5.54, p = 0.05). In PS matched cohorts adjusted for these factors, median PFS with Ctx after ICIs was 2.3 months (95% IC 1.8-5.3) and after TAs was 3.2 months (95% CI 2.3-5.3; HR 1.01, 95% IC 0.59-1.74; p = 0.96).
Conclusions
Despite the numerically higher RR with Ctx after exposure to ICIs versus TAs (16.4% versus 7.7%), differences were not statistically significant and did not associate with improved median PFS after adjusting for clinico-pathological determinants of response to Ctx in advanced solid tumors. Larger prospectively designed cohorts are needed to validate this hypothesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d´Hebron Institute of Oncology (VHIO).
Funding
Has not received any funding.
Disclosure
J. Martin-Liberal: Speaker Bureau / Expert testimony: Astellas; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pierre Fabre; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: ipsen. C. Hierro: Research grant / Funding (institution): Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Lilly; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ignyta; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche. I. Brana: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Merck; Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (self): Celgene; Research grant / Funding (self): giknik; Research grant / Funding (self): GSK; Research grant / Funding (self): Janssen; Research grant / Funding (self): Kura; Honoraria (self): Novartis; Research grant / Funding (self): Orion; Research grant / Funding (institution): Pfizer. M. Vieito Villar: Travel / Accommodation / Expenses: Roche. C. Saura: Speaker Bureau / Expert testimony, .: Roche. T. Macarulla Mercade: Honoraria (self): Genzyme; Honoraria (self), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self): Tesario; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Shire; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Advisory / Consultancy: QDE; Advisory / Consultancy, Travel / Accommodation / Expenses: H3B; Advisory / Consultancy: Baxalta; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Agios; Research grant / Funding (institution): Aslan; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution): Genentech. E. Muñoz-Couselo: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Dohme; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Roche. J. Tabernero: Honoraria (self), Josep Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics.: Josep Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limi. R. Dienstmann: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Symphogen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servier; Research grant / Funding (self): Merck. E. Garralda: Advisory / Consultancy: Roche; Advisory / Consultancy: Ellipses Pharma ; Advisory / Consultancy: Neomed; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Janssen Global Services; Speaker Bureau / Expert testimony: BMS; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Glycotope; Travel / Accommodation / Expenses: Menarini. All other authors have declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract